SG11201600038UA - Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof - Google Patents

Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof

Info

Publication number
SG11201600038UA
SG11201600038UA SG11201600038UA SG11201600038UA SG11201600038UA SG 11201600038U A SG11201600038U A SG 11201600038UA SG 11201600038U A SG11201600038U A SG 11201600038UA SG 11201600038U A SG11201600038U A SG 11201600038UA SG 11201600038U A SG11201600038U A SG 11201600038UA
Authority
SG
Singapore
Prior art keywords
pyrazolo
pyridines
benzyl
Prior art date
Application number
SG11201600038UA
Inventor
Alexandros Vakalopoulos
Alexey Gromov
Markus Follmann
Damian Brockschnieder
Johannes-Peter Stasch
Tobias Marquardt
Adrian Tersteegen
Frank Wunder
Gorden Redlich
Dieter Lang
Volkhart Min-Jian Li
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201600038UA publication Critical patent/SG11201600038UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
SG11201600038UA 2013-07-10 2014-07-08 Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof SG11201600038UA (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP13175904 2013-07-10
EP13175894 2013-07-10
EP13175889 2013-07-10
EP13175898 2013-07-10
EP13175890 2013-07-10
EP13175895 2013-07-10
EP13175899 2013-07-10
EP13175903 2013-07-10
EP13175892 2013-07-10
EP13175896 2013-07-10
PCT/EP2014/064547 WO2015004105A1 (en) 2013-07-10 2014-07-08 Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof

Publications (1)

Publication Number Publication Date
SG11201600038UA true SG11201600038UA (en) 2016-02-26

Family

ID=51162805

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600038UA SG11201600038UA (en) 2013-07-10 2014-07-08 Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof

Country Status (22)

Country Link
US (1) US9605008B2 (en)
EP (1) EP3019506A1 (en)
JP (1) JP2016523944A (en)
KR (1) KR20160030541A (en)
CN (1) CN105745215A (en)
AP (1) AP2016008970A0 (en)
AU (1) AU2014289312A1 (en)
CA (1) CA2917682A1 (en)
CL (1) CL2016000030A1 (en)
CU (1) CU20160004A7 (en)
DO (1) DOP2016000006A (en)
EA (1) EA201600096A1 (en)
GT (1) GT201600002A (en)
IL (1) IL243525A0 (en)
MX (1) MX2016000258A (en)
PE (1) PE20160201A1 (en)
PH (1) PH12016500065A1 (en)
SG (1) SG11201600038UA (en)
TN (1) TN2016000006A1 (en)
TW (1) TW201542569A (en)
UY (1) UY35652A (en)
WO (1) WO2015004105A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012200349A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted fused pyrimidines and triazines and their use
BR112017023855A2 (en) 2015-05-06 2018-07-17 Bayer Pharma Aktiengesellschaft the use of separate sgc stimulants, scg activators and combinations with pde5 inhibitors for the treatment of multiple sclerosis (ssc) concurrent digital (du) ulcers
EP3325013B2 (en) 2015-07-23 2023-07-19 Bayer Pharma Aktiengesellschaft Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and an angiotensin aii-antagonist and the use thereof
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017121692A1 (en) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituted sulfamides and use of same
WO2017121700A1 (en) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase
EP3525778A1 (en) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
EP3525779A1 (en) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Combination containing sgc stimulators and mineralocorticoid receptor antagonists
AU2018252099B2 (en) 2017-04-11 2021-08-12 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se Substituted cyclopropyl derivatives
CN112384213A (en) 2018-05-15 2021-02-19 拜耳公司 1, 3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8601208A1 (en) 1984-11-26 1985-11-01 Fordonal Sa Prepn. of a pyrazine derivative as gastric secretion inhibitor
JPS63139949A (en) 1986-12-02 1988-06-11 Fuji Photo Film Co Ltd Novel pyrazolone dye
SE8704248D0 (en) 1987-10-30 1987-10-30 Haessle Ab MEDICAL USE
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
JPH11505524A (en) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 Imidazo 1,2-A pyridine and imidazo 1,2-A pyrididine derivatives and their use as bone resorption inhibitors
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
DE59713007D1 (en) 1996-10-14 2009-06-25 Bayer Healthcare Ag NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEART CIRCULATION DISEASES
DE19642255A1 (en) 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19834044A1 (en) 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE10021069A1 (en) 2000-04-28 2001-10-31 Bayer Ag Substituted pyrazole derivative
JP4524072B2 (en) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
ES2231581T3 (en) 2000-11-22 2005-05-16 Bayer Healthcare Ag NEW DERIVATIVES OF PIRAZOLOPIRIDINE REPLACED WITH LACTAMA.
DE10132416A1 (en) 2001-07-04 2003-01-16 Bayer Ag New morpholine-bridged pyrazolopyridine derivatives
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
DE10232571A1 (en) 2002-07-18 2004-02-05 Bayer Ag 4-amino substituted pyrimidine derivatives
DE602004029025D1 (en) 2003-05-09 2010-10-21 Asahi Glass Co Ltd PROCESS FOR PREPARING 3-SUBSTITUTED 2-CHLORO-5-FLUORO-PYRIDINE BZW. A SALT OF IT
CN100355732C (en) 2003-11-03 2007-12-19 上海药明康德新药开发有限公司 Preparation of 2-Cl-5-F-nicotinate and nicotonic acid
CN101146796A (en) 2005-01-26 2008-03-19 先灵公司 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
WO2006130673A1 (en) 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
DE102006043443A1 (en) 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
EP2176261B1 (en) 2007-07-31 2012-12-19 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP2011513483A (en) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrimidines and pyridines useful as inhibitors of protein kinases
EP2373317B1 (en) * 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
DE102009004245A1 (en) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use
EP2432776B1 (en) 2009-05-21 2019-09-11 Universite Laval Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
DE102010021637A1 (en) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituted 5-fluoro-1H-pyrazolopyridines and their use
EP2575473B1 (en) 2010-05-27 2016-01-20 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
BR112013000596A2 (en) 2010-07-09 2019-09-24 Bayer Intelectual Property Gmbh fused pyridines and thiazines and their uses.
US8765769B2 (en) 2010-07-09 2014-07-01 Bayer Intellectual Property Gmbh Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases
WO2012030681A1 (en) 2010-08-31 2012-03-08 Dow Agrosciences Llc Pesticidal compositions
DE102010040234A1 (en) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Process for the preparation of 5-fluoro-1H-pyrazolo [3,4-b] pyridine-3-carbonitrile
DE102010040233A1 (en) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclic aza heterocycles and their use
DE102010043380A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituted carbamates and their use
US9090610B2 (en) * 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
CA2834901A1 (en) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituted imidazopyridines and imidazopyridazines and the use thereof
BR112013030909A2 (en) 2011-05-30 2016-12-06 Astellas Pharma Inc imidazopyridine compounds
AU2012280246A1 (en) * 2011-07-06 2014-01-23 Bayer Intellectual Property Gmbh Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
BR112014004569A2 (en) 2011-09-01 2017-06-13 F. Hoffmann-La Roche Ag compound of formula I, methods for treating inflammatory condition, rheumatoid arthritis, asthma and immune disorder, pharmaceutical composition and use of the compound
PE20141582A1 (en) * 2011-09-02 2014-11-06 Bayer Ip Gmbh SUBSTITUTED RINGED PYRIMIDINES AND USE OF THEM
DE102012200360A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted triazines and their use
DE102012200349A1 (en) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted fused pyrimidines and triazines and their use
DE102012200352A1 (en) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted, fused imidazoles and pyrazoles and their use
CN104395313B (en) 2012-03-06 2017-03-08 拜耳知识产权有限责任公司 Azabicyclo replacing and application thereof
WO2014131741A1 (en) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Benzyl-substituted pyrazolopyridines and use thereof
CN105308055B (en) 2013-03-01 2017-07-14 拜耳制药股份公司 Annelated pyrimidines class of trifluoromethyl substitution and application thereof
CA2920559A1 (en) 2013-08-08 2015-02-12 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyrazinecarboxamides and use thereof

Also Published As

Publication number Publication date
CN105745215A (en) 2016-07-06
CA2917682A1 (en) 2015-01-15
AP2016008970A0 (en) 2016-01-31
JP2016523944A (en) 2016-08-12
CL2016000030A1 (en) 2016-08-19
WO2015004105A1 (en) 2015-01-15
DOP2016000006A (en) 2016-02-15
IL243525A0 (en) 2016-02-29
GT201600002A (en) 2018-12-19
MX2016000258A (en) 2016-04-28
CU20160004A7 (en) 2016-06-29
AU2014289312A1 (en) 2016-02-11
EP3019506A1 (en) 2016-05-18
EA201600096A1 (en) 2016-10-31
US20160145271A1 (en) 2016-05-26
UY35652A (en) 2015-01-30
US9605008B2 (en) 2017-03-28
PH12016500065A1 (en) 2016-07-04
KR20160030541A (en) 2016-03-18
TW201542569A (en) 2015-11-16
TN2016000006A1 (en) 2017-07-05
PE20160201A1 (en) 2016-05-06

Similar Documents

Publication Publication Date Title
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
IL243525A0 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
HK1220373A1 (en) Il-33 antagonists and uses thereof il-33
EP2968304A4 (en) 4-phenylpiperidines, their preparation and use
EP2968303A4 (en) Octahydrocyclopentapyrroles, their preparation and use
IL236036A0 (en) Pyridinone and pyridazione derivatives
IL233863A (en) Pyridone derivatives, compositions comprising the same and uses thereof
IL246439A0 (en) Ring-contracted morphinans and the use thereof
HK1212980A1 (en) Pyridinone derivatives, preparation process and pharmaceutical use thereof
IL239643A0 (en) Substituted morphinans and the use thereof
IL245101A0 (en) 1,4-cyclohexylamine derivatives and processes for the preparation thereof
EP2951177A4 (en) Imidazopyridine compounds and uses thereof
HK1216890A1 (en) Benzyl substituted pyrazolopyridines and use thereof
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
IL244214B (en) Thienopiperidine derivative and use thereof
HK1225723A1 (en) Substituted imidazo[1,2-a]pyridinecarboxamides and their use
IL246167A0 (en) Berberine formulations and uses thereof
EP2837627A4 (en) Amidopyridine derivative, and use thereof
EP3072892A4 (en) Pyridine derivative and medical use thereof
EP2874994A4 (en) 3,5,n-trihydroxy-alkanamide and derivatives: method for making same and use thereof
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
PT2980096T (en) 2 ,3 ,5 -trihydroxy-androst-6-one and preparation methods and use thereof
EP2970495A4 (en) Fam150a, fam150b, and fam150 antagonists and uses thereof
HUE032883T2 (en) Polyols, their preparation and use
GB201300892D0 (en) Novel isothiazolo[4,3-b]pyridines